Multi-gene risk score for prediction of clinical outcomes in treatment-naïve metastatic castrate-resistant prostate cancer
JNCI Cancer Spectrum · 03.03.2025 · 9 (2)
DOI: 10.1093/jncics/pkaf025 ↗Kurz gefasst
Fachartikel in der Zeitschrift JNCI Cancer Spectrum, online erschienen am 28.02.2025. Verfasst von Muhammad Zaki Hidayatullah Fadlullah und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, DNA Copy Number Variations. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Background
To determine the performance of a multi-gene copy number variation (MG-CNV) risk score in metastatic tissue and plasma biospecimens from treatment-naïve metastatic castration-resistant prostate cancer (mCRPC) patients for prediction of clinical outcomes.
Methods
The mCRPC tissue and plasma cell-free DNA (cfDNA) biospecimen sequencing results obtained from publicly accessed cohorts in dbGaP, cBioPortal, and an institutional mCRPC cohort were used to develop a MG-CNV risk score derived from gains in AR, MYC, COL22A1, PIK3CA, PIK3CB, NOTCH1 and losses in TMPRSS2, NCOR1, ZBTB16, TP53, NKX3-1 in independent cohorts for determining overall survival (OS), progression-free survival (PFS) to first-line androgen receptor pathway inhibitors (ARPIs). The range of the risk scores for each cohort was dichotomized into “high-risk” and “low-risk” groups and association with OS/PFS determined. Univariate and multivariable Cox proportional hazards regressions were applied for survival analyses (P < .05 for statistical significance).
Results
Of 1137 metastatic tissue-plasma biospecimens across all cohorts, 699/1137 were treatment-naive mCRPC (235/699 metastatic tissue; 464/699 plasma-cfDNA), and 311/1137 were matched tissue-cfDNA pairs. In multivariable analysis, the MG-CNV risk score derived from metastatic tissue or in cfDNA was statistically significantly associated with OS with high score associated with short survival (hazard ratio = 2.65, confidence interval = 1.99 to 3.51; P = 1.35−11) and shorter PFS to ARPIs (median PFS of 7.8 months) compared with 14 months in patients with low-risk score.
Conclusions
A molecular risk score in treatment-naïve mCRPC state obtained either in metastatic tissue or cfDNA predicts clinical survival outcomes and offers a tumor biology-based tool to design biomarker-based enrichment clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States.
- Department of Biomedical Informatics, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States.
- Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
- Department of Medical Oncology, BC Cancer, Vancouver, BC, Canada.
- Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
- Division of Urology, Department of Surgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States.
ORCID-Profile: Muhammad Zaki Hidayatullah Fadlullah, David Nix, Cameron Herberts, Corinne Maurice-Dror, Alexander W Wyatt, Bogdana Schmidt, Aik-Choon Tan, Liang Wang, Manish Kohli
Förderung
- NCI NIH HHS
Zitieren
APA
Fadlullah, M. Z. H., Nix, D., Herberts, C., Maurice-Dror, C., Wyatt, A. W., Schmidt, B., Fairbourn, B., Tan, A. C., Wang, L., & Kohli, M. (2025). Multi-gene risk score for prediction of clinical outcomes in treatment-naïve metastatic castrate-resistant prostate cancer. JNCI Cancer Spectrum, 9(2). https://doi.org/10.1093/jncics/pkaf025
Vancouver
Fadlullah MZH, Nix D, Herberts C, Maurice-Dror C, Wyatt AW, Schmidt B, et al. Multi-gene risk score for prediction of clinical outcomes in treatment-naïve metastatic castrate-resistant prostate cancer. JNCI Cancer Spectrum. 2025;9(2). doi:10.1093/jncics/pkaf025
BibTeX
@article{Fadlullah2025,
author = {Fadlullah, Muhammad Zaki Hidayatullah and Nix, David and Herberts, Cameron and Maurice-Dror, Corinne and Wyatt, Alexander W and Schmidt, Bogdana and Fairbourn, Brayden and Tan, Aik-Choon and Wang, Liang and Kohli, Manish},
title = {Multi-gene risk score for prediction of clinical outcomes in treatment-naïve metastatic castrate-resistant prostate cancer},
journal = {JNCI Cancer Spectrum},
year = {2025},
volume = {9},
number = {2},
doi = {10.1093/jncics/pkaf025}
}
EUVIMED